JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

JNJ

168.27

-0.78%↓

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

VEEV

291.04

+0.02%↑

Search

Novartis AG

Închisă

117.59 0.37

Rezumat

Modificarea prețului

24h

Curent

Minim

116.09

Maxim

117.64

Indicatori cheie

By Trading Economics

Venit

418M

4B

Vânzări

660M

14B

P/E

Medie Sector

16.639

38.156

EPS

2.42

Randament dividend

3.5

Marjă de profit

28.18

Angajați

75,883

EBITDA

-5.8B

4.9M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-4.83% downside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.50%

2.50%

Statistici piață

By TradingEconomics

Capitalizare de piață

-18B

221B

Deschiderea anterioară

117.22

Închiderea anterioară

117.59

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Novartis AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iul. 2025, 14:26 UTC

Câștiguri

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 iul. 2025, 06:49 UTC

Câștiguri

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 iul. 2025, 05:41 UTC

Câștiguri

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

11 iun. 2025, 08:25 UTC

Achiziții, Fuziuni, Preluări

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

17 iul. 2025, 11:36 UTC

Market Talk

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 iul. 2025, 11:26 UTC

Market Talk

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 iul. 2025, 07:14 UTC

Market Talk

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 iul. 2025, 07:02 UTC

Market Talk
Câștiguri

Novartis's Results Look Impressive -- Market Talk

17 iul. 2025, 05:09 UTC

Câștiguri

Novartis 2Q Sales Grew 11% at Constant Currency

17 iul. 2025, 05:08 UTC

Câștiguri

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 iul. 2025, 05:06 UTC

Câștiguri

Novartis: Mehta's Appointment Is Effective March 2026

17 iul. 2025, 05:05 UTC

Câștiguri

Novartis: Harry Kirsch Retires After 22 Years With Company

17 iul. 2025, 05:05 UTC

Câștiguri

Novartis Names Mukul Mehta as CFO

17 iul. 2025, 05:04 UTC

Câștiguri

Analysts Saw Novartis 2Q Net Profit at $3.815B

17 iul. 2025, 05:04 UTC

Câștiguri

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

17 iul. 2025, 05:04 UTC

Câștiguri

Analysts Saw Novartis 2Q Sales at $14.17B

17 iul. 2025, 05:04 UTC

Câștiguri

Novartis 2Q Core Operating Profit $5.925B

17 iul. 2025, 05:04 UTC

Câștiguri

Novartis 2Q Oper Pft $4.86B

17 iul. 2025, 05:03 UTC

Câștiguri

Novartis 2Q Sales $14.05B

17 iul. 2025, 05:01 UTC

Câștiguri

Novartis: Buyback to Be Completed by End of 2027

17 iul. 2025, 05:01 UTC

Câștiguri

Novartis Starting Buyback of Up to $10B

17 iul. 2025, 05:01 UTC

Câștiguri

Novartis Backs 2025 Sales View

17 iul. 2025, 05:01 UTC

Câștiguri

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

17 iul. 2025, 05:01 UTC

Câștiguri

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

17 iul. 2025, 05:00 UTC

Câștiguri

Novartis Raises 2025 Earnings View

17 iul. 2025, 05:00 UTC

Câștiguri

Novartis AG 2Q Adj EPS $2.42

17 iul. 2025, 05:00 UTC

Câștiguri

Novartis AG 2Q Net Pft $4B

17 iul. 2025, 05:00 UTC

Câștiguri

Novartis AG 2Q EPS $2.07

9 iul. 2025, 10:59 UTC

Market Talk

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

2 iun. 2025, 14:17 UTC

Market Talk

Novartis's Pluvicto Delivers Positive Results in Third Late-Stage Trial -- Market Talk

Comparație

Modificare preț

Novartis AG Așteptări

Obiectiv de preț

By TipRanks

-4.83% jos

Prognoză pe 12 luni

Medie 111.79 USD  -4.83%

Maxim 139.377 USD

Minim 88 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovartis AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

0

Cumpărare

3

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 112.63Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Strong Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.